Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma

被引：1
|
作者：
Zimmermann, Julian [1 ]
Esser, E. [1 ]
Eter, N. [1 ]
Schuett, P. [2 ]
Uhlig, C. E. [1 ]
机构：
[1] Univ Klinikum Munster, Klin Augenheilkunde, Domagkstr 15, D-48149 Munster, Germany
[2] Onkol Gemeinschaftspraxis, Gutersloh, Germany
来源：
OPHTHALMOLOGIE | 2023年 / 120卷 / 07期
关键词：
D O I：
10.1007/s00347-022-01700-9
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：747 / 750
页数：4
相关论文
共 50 条
  • [41] Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S504
  • [42] Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease
    Sgherza, Nicola
    Curci, Paola
    Di Carlo, Gabriella
    Grande, Domenica
    Capozzi, Alessandro
    Ingravallo, Giuseppe
    De Marco, Luca
    Ferreri, Paolo
    Musto, Pellegrino
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1528 - 1531
  • [43] Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin
    Pessach, Ilias
    Argyrakopoulou, Georgia
    Petropoulos, Fotios
    Rapti, Irene
    Danglis, Fotios
    Trajce, Enkeleida
    Chandrinou, Eleni
    LEUKEMIA & LYMPHOMA, 2023, 64 (04) : 904 - 906
  • [44] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [45] Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
    Lassiter, Grace
    Bergeron, Cole
    Guedry, Ryan
    Cucarola, Julia
    Kaye, Adam M.
    Cornett, Elyse M.
    Kaye, Alan D.
    Varrassi, Giustino
    Viswanath, Omar
    Urits, Ivan
    CURRENT ONCOLOGY, 2021, 28 (01) : 640 - 660
  • [46] EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
    Tzogani, Kyriaki
    Penttil, Karri
    Lahteenvuo, Johanna
    Lapvetelainen, Tuomo
    Lopez Anglada, Lucia
    Prieto, Carolina
    Garcia-Ochoa, Blanca
    Enzmann, Harald
    Gisselbrecht, Christian
    Delgado, Julio
    Pignatti, Francesco
    ONCOLOGIST, 2021, 26 (01): : 70 - 76
  • [47] Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma
    Abeykoon, Jithma P.
    Vaxman, Julia
    Patel, Sanjay V.
    Kumar, Shaji
    Malave, Gabriella C.
    Young, Kimberly S.
    Ailawadhi, Sikander
    Larsen, Jeremy T.
    Dispenzieri, Angela
    Muchtar, Eli
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Leung, Nelson
    Warsame, Rahma
    Go, Ronald S.
    Bergsagel, Leif
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kapoor, Prashant
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (01) : 95 - 99
  • [48] Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma
    Popat, Rakesh
    Warcel, Dana
    O'Nions, Jenny
    Cowley, Anna
    Smith, Sasha
    Yong, Kwee
    Esposti, Simona Degli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E150 - E150
  • [49] A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
    Dileo, Rachel
    Mewawalla, Prerna
    Babu, Kalaivani
    Yin, Yue
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [50] Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
    Neupane, Karun
    Wahab, Ahsan
    Masood, Adeel
    Faraz, Tehniat
    Bahram, Saman
    Ehsan, Hamid
    Hannan, Abdul
    Anwer, Faiz
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 529 - 550
12345